ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AOR Aortech International Plc

126.50
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Aortech Share Discussion Threads

Showing 8376 to 8400 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
21/1/2020
07:48
Interesting development, moving the polymer business up the value chain and creating a centre of excellence for device companies to go to toget things made. Best is they are responding to market demand so potential customers are ready for RUA
landy90
21/1/2020
07:40
Little by little Aortech seems to be getting the ducks lined up.
langland
21/1/2020
07:28
AorTech International PLC

("AorTech", the "Company" or the "Group")

Extension to Agreement with RUA Medical

AorTech International PLC (AIM: AOR.L), the licensor of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ) and developer of medical devices utilising the key properties of Elast-Eon(TM) , is pleased to announce an extension to its agreement with RUA Medical Devices Limited ("RUA Medical").

For over 18 months, AorTech and RUA Medical have been partnering on the development of soft tissue patches and large bore vascular grafts. This project has combined RUA Medical's expertise as an implantable fabric specialist and full service contract device developer and manufacturer with the outstanding biostable and biocompatible properties of Elast-Eon(TM) .

As a result, RUA Medical has been provided with, and developed, a substantial amount of know-how relating to the highly flexible manufacturing processes for Elast-Eon(TM) , which include extrusion, dip processing (casting and coating), spray coating (including electro spinning and ultrasonic) and moulding (including compression, injection and reaction injection moulding). A number of opportunities have recently been identified where third-party medical device companies are looking for both a polymer and manufacturing solution to address current design problems.

In order to satisfy these market requirements, the Company's agreement with RUA Medical has been extended to allow RUA Medical to offer device design and manufacturing services incorporating both Elast-Eon(TM) polymer and processing know-how to third party customers.

Caroline Stretton, Chief Executive Officer of RUA Medical, said: "RUA Medical is delighted how the partnership with AorTech has developed and believes that RUA Medical is becoming a centre of excellence for the manufacture of Elast-Eon(TM) enabled devices and components. We look forward to working closely with the AorTech team to further expand the uses and opportunities for Elast-Eon(TM) ."

Bill Brown, Chairman of AorTech, said: "I am delighted that AorTech has been able to extend and deepen its partnership with RUA Medical and the opportunities this will present. AorTech will be attending MD&M West next month alongside RUA Medical and I look forward to engaging with the device industry on the outstanding properties of Elast-Eon(TM) ."

someuwin
21/1/2020
07:03
Excellent news!
someuwin
20/1/2020
21:26
mikeh30, link doesn’t seem to work, but I think that’s the article I posted on 6th December, but direct from the Jerusalem Post:



Shows the potential market that Medibrane can help Elasteon penetrate via licences.

bones
20/1/2020
19:57
https://www.google.co.uk/amp/s/m.jpost.com/HEALTH-SCIENCE/Medibrane-CEO-New-technologies-to-treat-prevent-strokes-606096/amp
mikeh30
20/1/2020
15:26
correct wageslave - I mentioned several weeks ago that the market for AOR is very inelastic, which means small trades move the price significantly, in both directions.

H

herschel k
20/1/2020
14:44
That can also mean it falls very quickly as well.
wageslave
20/1/2020
13:57
A contributing factor is that there seems to be very little stock around.
langland
20/1/2020
13:47
Thanks Bones I'm sure you're right in general terms. One would expect a gradual rise as the market takes those points on board. Just odd that it should suddenly tick up by 10.45% this am!
cybernest53
20/1/2020
13:32
Cybernest, there has been a sheaf of positive announcements since late November and the share price has moved diddly-squat since then. At some point, the market may take the view that there is something positive happening in 2020 for Aortech and catching up with events after the end of year balancing off of accounts?
bones
20/1/2020
13:22
So is there a particular reason for this sudden tick up today?/ I can't find any tips or announcements.
cybernest53
20/1/2020
13:14
and:
4 July, 2018 |
LONDON (Alliance News) - AorTech International PLC has been granted a patent by the Brazilian Patent Office for its medical implant products known as biomedical gels.
Shares in AorTech were down 5.9% at 56.00 pence on Wednesday.

AorTech develops a range of materials that can be implanted into the body. Biomedical gels in particular are used to make and repair soft tissue products such as breast implants.

"Brazil is one of the largest markets for breast enhancement outside of the USA and is therefore an important patent territory," said Chairman Bill Brown.
On Thursday, AorTech signed a deal with medical equipment manufacturer RUA Medical to develop and supply two other implantable products with shares rising 16% in response.

25october1969
20/1/2020
13:13
Agreed Langland, that is what happened. I cant find it just now but in one of the AOR releases since the financing in May 2018, it was stated that the implant IP was taken back and the old licence terminated due to inaction by the licensee.
bones
20/1/2020
13:06
Surely Aortech took back control of this because the company did nothing with it?
langland
20/1/2020
13:01
mikeh30 you might find this an interesting read


hxxps://www.sec.gov/Archives/edgar/data/1688757/000162828018008184/exhibit109s-1.htm

25october1969
20/1/2020
12:49
https://patents.justia.com/assignee/aortech-international-plcYou only need to look at the amount of patents they hold.The breast implant on is a huge one that has been overlooked. Add on the new patents they discussed recently.
mikeh30
20/1/2020
12:08
Bought back in. Valuation looks a bit silly compared to peers. Should test recent highs
mikeh30
20/1/2020
12:01
Looking like a good start to the next leg up.
greedy rooster
20/1/2020
11:00
About time had a good move up here I think.
someuwin
15/1/2020
07:57
No problem and it is a good find. This must be a huge market worldwide. It would be great if AOR could tap into this with a OEM deal or deals.
langland
15/1/2020
07:54
Apologies Langland and many thanks for reposting.
It will teach me to wait till I’m properly awake when posting!

semper vigilans
15/1/2020
07:50
SV,

I have taken the liberty of copying your post from the old thread. I hope you don't mind.

Semper Vigilans15 Jan '20 - 03:56 - 4729 of 4729
0 0 0
Interesting article concerning hernia mesh problems.

langland
15/1/2020
03:56
Interesting article concerning hernia mesh problems.
semper vigilans
14/1/2020
15:49
I agree with you there Stig on the bio/medtechs potential as the Woodford thing recedes. Let’s hope these forces align to give us a slingshot effect.
bones
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older

Your Recent History

Delayed Upgrade Clock